Artal Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Artal Group’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,500,000	Closed	-$24.3M	–	159
2021 Q2	$24.3M	Hold	2,500,000	–	–	0.49%	44
2021 Q1	$26.9M	Buy	2,500,000 +400,000	+19%	+$4.95M	0.47%	50
2020 Q4	$30.9M	Buy	2,100,000 +600,000	+40%	+$8.65M	0.66%	41
2020 Q3	$21.3M	Buy	1,500,000 +547,000	+57%	+$5.45M	0.52%	42
2020 Q2	$7.71M	Sell	953,000 -47,000	-5%	-$291K	0.22%	83
2020 Q1	$4.04M	Buy	+1,000,000	New	+$3.78M	0.17%	81
2019 Q2	–	Sell	-150,000	Closed	-$99K	–	125
2019 Q1	$99K	Hold	150,000	–	–	﹤0.01%	104
2018 Q4	$257K	Hold	150,000	–	–	0.01%	103
2018 Q3	$870K	Hold	150,000	–	–	0.02%	101
2018 Q2	$900K	Hold	150,000	–	–	0.02%	100
2018 Q1	$1.08M	Hold	150,000	–	–	0.01%	104
2017 Q4	$1.09M	Buy	+150,000	New	+$1.24M	0.02%	110

Other funds holding TRIL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

OPU

Omni Partners US Irvine, California $1.95B AUM

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Artal Group's TRIL Position: Q3 2021 in Review

Artal Group sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 2,500,000 shares — an estimated $24.3M sold.

Artal Group first reported a position in TRIL in Q4 2017 and held it in 12 quarters. The position peaked at $30.9M in Q4 2020. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

Artal Group reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
Artal Group sold 2,500,000 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $24.3M.
Artal Group first reported a position in Trillium Therapeutics Inc. in Q4 2017 and held it in 12 quarters.
Artal Group's Trillium Therapeutics Inc. position peaked at $30.9M in Q4 2020.
181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Artal Group's 13F filing for Q3 2021, filed 12 Nov 2021.